Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Mar;14(3):276-86.

Matrix metalloproteinases: drug targets for myocardial infarction

Andriy Yabluchanskiy  1 , Yaojun Li, Robert J Chilton, Merry L Lindsey
Affiliations
Review

Matrix metalloproteinases: drug targets for myocardial infarction

Andriy Yabluchanskiy et al. Curr Drug Targets. 2013 Mar.

Abstract

Myocardial infarction (MI) remains a major cause of morbidity and mortality worldwide. Rapid advances in the treatment of acute MI have significantly improved short-term outcomes in patients, due in large part to successes in preventing myocardial cell death and limiting infarct area during the time of ischemia and subsequent reperfusion. Matrix metalloproteases (MMPs) play key roles in post-MI cardiac remodeling and in the development of adverse outcomes. This review highlights the importance of MMPs in the injury and remodeling response of the left ventricle and also discusses their potential as therapeutic targets Additional pre-clinical and clinical research is needed to further investigate and understand the cardioprotective effects of MMPs inhibitors.

PubMed Disclaimer

Figures

Figure 1
Figure 1
MMP subsites as targets for different classes of MMP inhibitors. Pre – a signal sequence pre-domain, Pro – pro-catalytic domain, Catalytic – catalytic domain, Zn2+ - metal center of the catalytic domain, Hemopexin – hemopexin-like domain (absent in MMP-7 and MMP-26) [142, 143].
Figure 2
Figure 2
Medications used post-MI that directly or indirectly affect MMP production or activity.
See this image and copyright information in PMC

References

    1. Hein S, Schaper J. The extracellular matrix in normal and diseased myocardium. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. 2001;8(2):188–196. Epub 2001/04/11. - PubMed
    1. Hobeika MJ, Thompson RW, Muhs BE, Brooks PC, Gagne PJ. Matrix metalloproteinases in peripheral vascular disease. Journal of vascular surgery : official publication, the Society for Vascular Surgery [and] International Society for Cardiovascular Surgery, North American Chapter. 2007;45(4):849–857. Epub 2007/04/03. - PubMed
    1. Pelouch V, Dixon IM, Golfman L, Beamish RE, Dhalla NS. Role of extracellular matrix proteins in heart function. Mol Cell Biochem. 1993;129(2):101–120. - PubMed
    1. Taipale J, Keski-Oja J. Growth factors in the extracellular matrix. Faseb J. 1997;11(1):51–59. - PubMed
    1. Lindsey ML, Borg TK. Understanding the role of the extracellular matrix in cardiovascular development and disease: where do we go from here? Journal of molecular and cellular cardiology. 2010;48(3):431–432. - PMC - PubMed

Publication types

LinkOut - more resources